

PROVIDER BULLETIN

PROVIDER INFORMATION



March 1, 2023

Medical Policy Updates: Coupe Health and Self-Funded Benefit Plans managed by Blue Cross and Blue Shield of Alabama

Participating providers are invited to submit for consideration scientific, evidence-based information, professional consensus opinions, and other information supported by medical literature relevant to our draft policies for Coupe Health and Self-Funded benefit plans managed by Blue Cross and Blue Shield of Alabama.

The draft policies are available for physician comment for 45 days from the posting date found on the document. At the conclusion of the 45 days, policies will go into effect. Make sure your voice is heard by providing feedback directly to us.

How to Submit Comments on Draft Medical Policies

[Complete our medical policy feedback form](https://mn-policies.exploremyplan.com/portal/web/mn-policies/feedback) online at <https://mn-policies.exploremyplan.com/portal/web/mn-policies/feedback> or send comments and supporting documentation to us by mail or fax:

Birmingham Service Center
Attn: Health Management - Medical Policy
P.O. Box 10527
Birmingham, AL 35202
Fax: 205-220-0878

Draft Medical Policies

Draft medical policies can be found at [Policies & Guidelines \(exploremyplan.com\)](https://mn-policies.exploremyplan.com/portal/web/mn-policies/feedback)

Policy #	Policy Title
MP-387	Hematopoietic Cell Transplantation for Non-Hodgkin Lymphomas
MP-483	Transcatheter Aortic-valve Implantation for Aortic Stenosis
MP-752	Stationary Ultrasonic Diathermy Devices
MP-170	Transcranial Magnetic Stimulation as a Treatment of Depression and Other Psychiatric Disorders

Draft Provider-Administered Drug Policies

Draft provider-administered drug policies can be found at [Policies & Guidelines \(exploremyplan.com\)](https://mn-policies.exploremyplan.com/portal/web/mn-policies/feedback) and [Policies & Guidelines \(exploremyplan.com\)](https://mn-policies.exploremyplan.com/portal/web/mn-policies/feedback)

Policy #	Policy Title
PH-90421	Gamifant™ (emapalumab-lzsg)
PH-90514	Givlaari® (givosiran)

P14-23
Distribution: bluecrossmn.com/providers/forms-and-publications

Policy #	Policy Title
PH-90080	Leuprolide Suspension: Lupron Depot®, Lupron Depot-Ped®, Eligard®, Fensolvi®, Camcevi™, Lutrate Depot™
PH-90350	Luxturna® (voretigene neparvovec-rzyl)
PH-90512	Scenesse® (afamelanotide)
PH-90687	Tzield™ (teplizumab-mzwv)